Primary Site >> Colorectal Cancer
Gene >> CAP1
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
Ref: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. PMID: 7629885 |
Ref: The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. PMID: 11606396 |
Ref: Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. PMID: 16115944 |
Ref: Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. PMID: 17363612 Ref: Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide. PMID: 17564703 |
Ref: Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. PMID: 18209048 |
Ref: HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. PMID: 20386466 |
Ref: Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. PMID: 27091407 |